Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.18 CHF -1.64% Market Closed
Market Cap: 143.3m CHF
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 16.76 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

NWRN Lowest Forecast
Wall Street Target
11.62 CHF
62% Upside
NWRN Average Forecast
Wall Street Target
16.76 CHF
133% Upside
NWRN Highest Forecast
Wall Street Target
26.25 CHF
266% Upside
Lowest
Price Target
11.62 CHF
62% Upside
Average
Price Target
16.76 CHF
133% Upside
Highest
Price Target
26.25 CHF
266% Upside
Newron Pharmaceuticals SpA Competitors:
Price Targets
PBH
Prestige Consumer Healthcare Inc
14% Upside
O
ORNBV
Orion Oyj
5% Upside
LAURUSLABS
Laurus Labs Ltd
12% Downside
U
3933
United Laboratories International Holdings Ltd
17% Upside
PBH
Prestige Consumer Healthcare Inc
14% Upside
O
ORNBV
Orion Oyj
5% Upside
LAURUSLABS
Laurus Labs Ltd
12% Downside
U
3933
United Laboratories International Holdings Ltd
17% Upside
BMY
Bristol-Myers Squibb Co
22% Upside
000756
Shandong Xinhua Pharmaceutical Co Ltd
24% Downside
4528
Ono Pharmaceutical Co Ltd
23% Upside

Revenue
Forecast

Revenue Estimate
Newron Pharmaceuticals SpA

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 35%. The projected CAGR for the next 3 years is 35%.

35%
Past Growth
35%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Newron Pharmaceuticals SpA

The compound annual growth rate of Newron Pharmaceuticals SpA's operating income for the next 3 years is 55%.

N/A
Past Growth
55%
Estimated Growth
Estimates Accuracy
-26%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

See Also

Summary
NWRN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NWRN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NWRN stock valuation using valuation multiples.
Wall Street Estimates
NWRN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NWRN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NWRN's stock price target?
Price Target
16.76 CHF

According to Wall Street analysts, the average 1-year price target for NWRN is 16.76 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
35%

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 35%. The projected CAGR for the next 3 years is 35%.

What is Newron Pharmaceuticals SpA's Operating Income forecast?
Projected CAGR
55%

The compound annual growth rate of Newron Pharmaceuticals SpA's operating income for the next 3 years is 55%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.